Immuneering Corp Dossier - Source-backed chat

Immuneering Corp

IMRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.59

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.03Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $260.7M

Enterprise Value $219.4M

Shares Outstanding 72.9M diluted

Next Earnings Date31 Dec 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Immuneering Corp is a late-stage clinical oncology company pioneering Deep Cyclic Inhibitors (DCIs) designed to target the MAPK pathway with high durability and low toxicity. The company's lead candidate, atebimetinib (IMM-1-104), recently demonstrated an extraordinary 17.3-month median overall survival (OS) in an expanded Phase 2a cohort of 55 first-line metastatic pancreatic cancer patients, more than doubling the historical standard of care benchmark of 8.5 months. With the global Phase 3 MAPKeeper 301 trial already underway and the first patient dosed in June 2026, Immuneering is well-positioned to disrupt the frontline pancreatic cancer landscape. Backed by a robust cash position of $198.6 million providing a runway into 2029, the company offers a highly compelling risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$18.86

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0015%

The Phase 3 MAPKeeper 301 trial fails to replicate the survival benefit observed in the Phase 2a trial, or shows a narrower-than-expected efficacy gap against standard GnP. Alternatively, safety concerns or unexpected toxicities emerge in larger patient populations, limiting the drug's combinability. Delays in clinical execution or partner-led trials (such as the NSCLC study with Regeneron) extend the development timeline, forcing the company to raise highly dilutive capital before reaching key readouts.

Base CaseCentral scenario

$16.5060%

The Phase 3 MAPKeeper 301 trial progresses on track with steady enrollment, maintaining the anticipated mid-2028 topline readout. The survival trend remains strong, and the combination of atebimetinib + Libtayo in NSCLC successfully initiates dosing in 2H 2026. The company's cash runway remains sufficient into 2029, minimizing near-term dilution risks. Wall Street consensus reflects a highly favorable outlook on the clinical data, driving steady valuation recovery toward historical averages.

Bull CaseUpside scenario

$30.0025%

The Phase 3 MAPKeeper 301 trial successfully replicates the Phase 2a survival signal, demonstrating a statistically significant and clinically meaningful OS benefit over standard GnP. Atebimetinib receives FDA approval as a first-line therapy for metastatic pancreatic cancer, capturing substantial market share due to its superior tolerability profile (e.g., weight preservation and low Grade 3+ non-chemo toxicities). Additionally, the combination with Libtayo in NSCLC yields positive Phase 2 data, validating the DCI platform across multiple solid tumor indications and attracting lucrative biopharma partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Exceptional Phase 2a clinical efficacy, showing a 17.3-month median OS in first-line metastatic pancreatic cancer compared to the historical 8.5-month benchmark.
Differentiated Deep Cyclic Inhibition (DCI) mechanism that pulses pathway inhibition to prevent tumor resistance while sparing healthy cells, resulting in superior tolerability and weight preservation.
Strong balance sheet with $198.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, securing an operational runway into 2029.
Pivotal Phase 3 MAPKeeper 301 trial is actively recruiting and has dosed its first patient as of June 11, 2026, establishing a clear registrational pathway.

Key Investment Risks

Clinical development risk inherent in replicating Phase 2a single-arm results in a larger, randomized Phase 3 trial.
High dependence on a single lead asset (atebimetinib) for near-to-mid-term valuation.
Potential for future equity dilution if clinical timelines extend or if additional pipeline programs require accelerated funding.
Execution and recruitment risks associated with running a global, multi-center Phase 3 clinical trial.

Thesis Invalidation Triggers

Failure of the Phase 3 MAPKeeper 301 trial to meet its primary endpoint of overall survival.
Emergence of severe, unexpected treatment-emergent adverse events (TEAEs) that compromise the safety and combinability profile of atebimetinib.
Significant delays in patient enrollment for the Phase 3 trial, pushing the topline readout timeline past mid-2028.
Termination or material delay of the clinical supply agreement with Regeneron for the NSCLC trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.